TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10644101

Group type: EXPERIMENTAL
Intervention: Water-soluble contrast material (WSCM)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Oil-soluble contrast material (OSCM)
Number of subjects: 666

Group type: EXPERIMENTAL
Intervention: Both OSCM and WSCM
Number of subjects: 666

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 666
Study: 9242302

Group type: EXPERIMENTAL
Intervention: Saccades toward visual single- and double-step stimuli
Number of subjects: 0
Study: 8304889

Group type: EXPERIMENTAL
Intervention: Hexoprenaline
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Ritodrine
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 3653970

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Hypertensive patients (women)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Hypertensive patients (blacks)
Number of subjects: 107
Study: 29396785

Group type: EXPERIMENTAL
Intervention: LESSOP-DN
Number of subjects: 99

Group type: COMPARATOR
Intervention: MLDN
Number of subjects: 99
Study: 27472280

Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25691114

Group type: EXPERIMENTAL
Intervention: Implementation of WHO surgical safety checklist (Rc arm)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (Rn arm)
Number of subjects: 700
Study: 24325105

Group type: EXPERIMENTAL
Intervention: High doses Ulinastatin (20,000 U/kg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low doses Ulinastatin (5,000 U/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 90
Study: 20828230

Group type: EXPERIMENTAL
Intervention: Truth effect measured by rating previously seen statements as true or false.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Familiarity with opposite sets of statements.
Number of subjects: 74
Study: 18405789

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alogliptin 50 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alogliptin 100 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alogliptin 200 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alogliptin 400 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alogliptin 800 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 17142537

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-acting beta agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specialty care
Number of subjects: 0
Study: 12945220

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 547
Study: 10714531

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulation aimed at correcting SI-joint dysfunction
Number of subjects: 28

Group type: COMPARATOR
Intervention: No joint manipulation (Control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulation
Number of subjects: 28
Study: 9176996

Group type: EXPERIMENTAL
Intervention: 400 mg (+)S-ibuprofen arginine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 400 mg (−)R-ibuprofen arginine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 800 mg racemic ibuprofen arginine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 400 mg (+)S-ibuprofen arginine and 400 mg (−)R-ibuprofen arginine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (−)R-ibuprofen arginine
Number of subjects: 7
Study: 1585758

Group type: EXPERIMENTAL
Intervention: Micanol with thorough application information
Number of subjects: 29

Group type: COMPARATOR
Intervention: Micanol with standard patient information
Number of subjects: 29
Study: 4037034

Group type: EXPERIMENTAL
Intervention: 20 mg nadolol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40 mg nadolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29633043

Group type: EXPERIMENTAL
Intervention: Ultrasonic energy-based surgical device (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monopolar energy-based surgical device (n=20)
Number of subjects: 40
Study: 28029312

Group type: EXPERIMENTAL
Intervention: SNP88 risk score
Number of subjects: 995

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 995

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: TC model
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Combined SNP88 and TC model
Number of subjects: 995
Study: 26678637

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (IL-6)
Number of subjects: 6187

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 6187

Group type: EXPERIMENTAL
Intervention: IL-6 (after adjustment for cardiac and renal biomarkers)
Number of subjects: 6187

Group type: EXPERIMENTAL
Intervention: CRP (after adjustment for cardiac and renal biomarkers)
Number of subjects: 6187

Group type: EXPERIMENTAL
Intervention: IL-6 (added to CHA2DS2-VASc risk score)
Number of subjects: 6187

Group type: EXPERIMENTAL
Intervention: Fibrinogen
Number of subjects: 6187
Study: 24524601

Group type: COMPARATOR
Intervention: Atorvastatin 20 mg qn or other statin equivalent to 20 mg atorvastatin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Statin plus bezafibrate 200 mg bid
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 104
Study: 21037270

Group type: EXPERIMENTAL
Intervention: Written action plan adherence
Number of subjects: 252
Study: 18694978

Group type: EXPERIMENTAL
Intervention: Load group (priming dose of 0.07 units of regular insulin per kg body weight followed by 0.07 unit x kg(‐1) x h(‐1) i.v.)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Twice no load group (infusion of regular insulin of 0.14 x kg(‐1) x h(‐1) without a loading dose)
Number of subjects: 37

Group type: COMPARATOR
Intervention: No load group (infusion of regular insulin of 0.07 unit . kg body weight(‐1) x h(‐1) without a loading dose)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Comparison of all groups
Number of subjects: 37
Study: 16534238

Group type: EXPERIMENTAL
Intervention: OKT3 therapy in addition to tacrolimus
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control cohort (cadaveric renal transplant patients from 1995)
Number of subjects: 50
Study: 12751506

Group type: EXPERIMENTAL
Intervention: Lidocaine iontophoresis (4% lidocaine, 4 ml for 10 min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Local infiltration of lidocaine (1% lidocaine, 1 ml)
Number of subjects: 30
Study: 10687338

Group type: EXPERIMENTAL
Intervention: MS:DM (morphine sulfate and dextromethorphan hydrobromide)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: MS:DM
Number of subjects: 321

Group type: COMPARATOR
Intervention: MS
Number of subjects: 321
Study: 9494946

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (0, 7, 14, or 21 mg doses)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (0 mg nicotine)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine and abstinence from smoking
Number of subjects: 66
Study: 8444088

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg at night
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg twice daily
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 3023556

Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (120 mg/m2 day 1) + etoposide (120 mg/m2 days 3, 5, and 7)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Standard-dose cisplatin (60 mg/m2 day 1) + etoposide (120 mg/m2 days 3, 5, and 7)
Number of subjects: 241
Study: 31275576

Group type: EXPERIMENTAL
Intervention: KOKO Plus (KP)
Number of subjects: 1273
Study: 28604990

Group type: EXPERIMENTAL
Intervention: Dynamic needle tip positioning (DNTP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Palpation technique
Number of subjects: 40
Study: 26233916

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 22878351

Group type: EXPERIMENTAL
Intervention: CAM2
Number of subjects: 15

Group type: COMPARATOR
Intervention: NAL‐NL2
Number of subjects: 15
Study: 21474529

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention (5 sessions)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Health promotion intervention (5 sessions)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 57

Group type: COMPARATOR
Intervention: Health promotion intervention
Number of subjects: 57
Study: 19703381

Group type: EXPERIMENTAL
Intervention: Lithium prescribed
Number of subjects: 84

Group type: COMPARATOR
Intervention: No lithium prescribed
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Overall ECT treatment
Number of subjects: 84
Study: 17276431

Group type: EXPERIMENTAL
Intervention: Ghrelin (1 microg/kg i.v. bolus)
Number of subjects: 35
Study: 15521161

Group type: EXPERIMENTAL
Intervention: 2 postcards
Number of subjects: 8881

Group type: COMPARATOR
Intervention: 1 postcard
Number of subjects: 8881

Group type: EXPERIMENTAL
Intervention: 1 postcard + tool kit
Number of subjects: 8881

Group type: EXPERIMENTAL
Intervention: 2 postcards + tool kit
Number of subjects: 8881
Study: 14742041

Group type: EXPERIMENTAL
Intervention: Asynchronous electronic small groups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Face-to-face small groups
Number of subjects: 0
Study: 9759414

Group type: EXPERIMENTAL
Intervention: Intracameral lidocaine 1%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 80
Study: 7836518

Group type: EXPERIMENTAL
Intervention: 3 mM pentoxifylline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (absence of pentoxifylline)
Number of subjects: 20
Study: 3403422

Group type: EXPERIMENTAL
Intervention: Cold air inhalation (3.6 degrees C)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Hot air inhalation (ambient air)
Number of subjects: 8
Study: 30175556

Group type: EXPERIMENTAL
Intervention: Herbal complex Soratinex® (Dr Michaels®) applied twice daily for 8 weeks
Number of subjects: 0
Study: 29178815

Group type: EXPERIMENTAL
Intervention: Core laboratory interpretation of coronary CT angiography
Number of subjects: 4347

Group type: COMPARATOR
Intervention: Site interpretation of coronary CT angiography
Number of subjects: 4347

Group type: EXPERIMENTAL
Intervention: Core laboratory interpretation
Number of subjects: 4347

Group type: COMPARATOR
Intervention: Site interpretation
Number of subjects: 4347

Group type: EXPERIMENTAL
Intervention: Overall outcomes
Number of subjects: 4347
Study: 28271733

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin Glulisine (IG) once daily (QD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin Glulisine (IG) three times daily (TID)
Number of subjects: 0
Study: 25343729

Group type: EXPERIMENTAL
Intervention: Mulberry leaf aqueous extract (MLAE) supplementation (5g/day)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 23238645

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 80
Study: 21574739

Group type: EXPERIMENTAL
Intervention: Pressure inducing distraction (performance-contingent outcomes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pressure inducing explicit monitoring (monitoring by others)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions designed to eliminate choking
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring-pressure in a procedural-based task (serial reaction time task)
Number of subjects: 0
Study: 18076740

Group type: EXPERIMENTAL
Intervention: Transparent retractable extension device (TRE)
Number of subjects: 895

Group type: COMPARATOR
Intervention: Standard colonoscopy without TRE
Number of subjects: 895

Group type: EXPERIMENTAL
Intervention: Hood-assisted colonoscopy
Number of subjects: 895

Group type: COMPARATOR
Intervention: Standard colonoscopy without hood
Number of subjects: 895
Study: 16931220

Group type: EXPERIMENTAL
Intervention: ANDY-Disc
Number of subjects: 270

Group type: COMPARATOR
Intervention: UltraBag
Number of subjects: 270
Study: 12649711

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 200 mg once daily for 5 days
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg once daily for 5 days
Number of subjects: 414

Group type: COMPARATOR
Intervention: Co-amoxiclav 500 mg amoxicillin/125 mg clavulanic acid t.i.d. for 10 days
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 200 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Gatifloxacin 400 mg
Number of subjects: 414

Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 414
Study: 10880892

Group type: EXPERIMENTAL
Intervention: Insulin lispro (LP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Insuman (I)
Number of subjects: 41
Study: 9366821

Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen (norgestimate/ethinyl estradiol)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 1287139

Group type: EXPERIMENTAL
Intervention: Ofloxacin (oral administration)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sulbactam-ampicillin (parenteral administration)
Number of subjects: 20
Study: 6489742

Group type: EXPERIMENTAL
Intervention: Preventive psychosocial intervention (N = 59), techniques to lower distress and improve coping over four weeks.
Number of subjects: 381

Group type: COMPARATOR
Intervention: Control group (N = 58), received no intervention.
Number of subjects: 381
Study: 31695482

Group type: EXPERIMENTAL
Intervention: Inhaled aromatherapy with peppermint essence
Number of subjects: 80

Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 80
Study: 30400937

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA) 100 mg/d, prescribed at night, starting from early pregnancy (12-20 weeks of gestation) until 34 weeks of gestation.
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Routine examinations (control group).
Number of subjects: 1000
Study: 27509102

Group type: EXPERIMENTAL
Intervention: Migalastat
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 23790018

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 20484899

Group type: EXPERIMENTAL
Intervention: Low-density lipoprotein apheresis (LA)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Statins
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study: 16367988

Group type: EXPERIMENTAL
Intervention: Methylphenidate (up to 0.6 mg/kg/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 11481263

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Technology (FDT)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Scanning Laser Polarimetry (SLP)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Short-Wavelength Automated Perimetry (SWAP)
Number of subjects: 94
Study: 9725543

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 20 mg
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Zolmitriptan (5 mg, 10 mg, 20 mg)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 7527325

Group type: EXPERIMENTAL
Intervention: Foscarnet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Foscarnet and zidovudine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ganciclovir
Number of subjects: 0
Study: 2567714

Group type: EXPERIMENTAL
Intervention: Daily FSH therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alternate-day FSH therapy
Number of subjects: 12
Study: 4156819

Group type: EXPERIMENTAL
Intervention: Xylitol (X) diet
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Fructose (F) diet
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sucrose (S) diet
Number of subjects: 125
Study: 30222768

Group type: EXPERIMENTAL
Intervention: Link4Health strategy (including point-of-care CD4+ count testing, accelerated ART initiation, mobile phone appointment reminders, care and prevention package, non-cash financial incentive)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 27427284

Group type: EXPERIMENTAL
Intervention: Experience-based decisions with large samples taken
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experience-based decisions with few samples taken
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Description-based decisions
Number of subjects: 0
Study: 25326742

Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 83

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 83
Study: 22706091

Group type: EXPERIMENTAL
Intervention: Disc prosthesis surgery
Number of subjects: 116

Group type: COMPARATOR
Intervention: Rehabilitation
Number of subjects: 116
Study: 20433807

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted subunit vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-adjuvanted subunit vaccine
Number of subjects: 0
Study: 18310480

Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Fluticasone/Salmeterol
Number of subjects: 289

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study: 15671109

Group type: EXPERIMENTAL
Intervention: 300 microg ENG daily and 400 mg TD every 4 weeks for 48 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: 300 microg ENG daily and 400 mg TD every 6 weeks for 48 weeks
Number of subjects: 112
Study: 12621386

Group type: EXPERIMENTAL
Intervention: Oral cisapride (0.07 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intravenous midazolam (0.025 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Oral midazolam (0.15 mg/kg)
Number of subjects: 17
Study: 10533454

Group type: EXPERIMENTAL
Intervention: 20 micrograms/kg of granisetron
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 40 micrograms/kg of granisetron
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 20 micrograms/kg and 40 micrograms/kg of granisetron
Number of subjects: 49
Study: 8901154

Group type: EXPERIMENTAL
Intervention: Fe‐gluc (2 x 50 mg Fe per day, per os) plus MAH (2 x 7.5 mmol Mg per day, p.o.)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fe‐gluc plus MAH
Number of subjects: 2

Group type: COMPARATOR
Intervention: Fe‐gluc alone
Number of subjects: 2
Study: 1651211

Group type: EXPERIMENTAL
Intervention: Low-sodium diet
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Potassium supplement administration
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo-treated control group
Number of subjects: 243

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 243
Study: 6616987

Group type: EXPERIMENTAL
Intervention: verapamil (0.1 mg/kg i.v., followed by an infusion of 0.01 mg/kg/min)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: nifedipin (20 mg sublingually)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: diltiazem (0.2 mg/kg i.v., followed by infusion of 0.02 mg/kg/min)
Number of subjects: 14
Study: 31280789

Group type: EXPERIMENTAL
Intervention: Self-screening tool and referral pathway pamphlet intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 70
Study: 29777665

Group type: EXPERIMENTAL
Intervention: S2S intervention group (text messages about sexual health)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (text messages about diet and/or exercise)
Number of subjects: 88
Study: 27502480

Group type: EXPERIMENTAL
Intervention: MAKINGtheLINK intervention group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 22
Study: 24500418

Group type: EXPERIMENTAL
Intervention: Tipifarnib (200 mg/m² orally every 12 hours)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 22180622

Group type: EXPERIMENTAL
Intervention: 3-dose regimen of intravenous artesunate (given at 0, 24, and 48 hours)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Conventional 5-dose regimen of intravenous artesunate (given at 0, 12, 24, 48, and 72 hours)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 3-dose regimen of intravenous artesunate
Number of subjects: 171

Group type: COMPARATOR
Intervention: 5-dose regimen of intravenous artesunate
Number of subjects: 171
Study: 20451215

Group type: EXPERIMENTAL
Intervention: CCK-4 (25 μg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CCK-4 (50 μg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (after CCK-4)
Number of subjects: 20
Study: 17333157

Group type: EXPERIMENTAL
Intervention: SP+AT (sulfadoxine/pyrimethamine + artesunate)
Number of subjects: 16

Group type: COMPARATOR
Intervention: SP (sulfadoxine/pyrimethamine)
Number of subjects: 16
Study: 16351364

Group type: EXPERIMENTAL
Intervention: Identity denial experiences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-perception of American identity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daily experiences of identity denial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reactions to identity denial
Number of subjects: 0
Study: 12063480

Group type: EXPERIMENTAL
Intervention: 20 U BTX‐A (BOTOX, Allergan, Inc) injected intramuscularly into 5 glabellar sites
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study: 10223776

Group type: EXPERIMENTAL
Intervention: Grapefruit juice
Number of subjects: 14

Group type: COMPARATOR
Intervention: Water
Number of subjects: 14
Study: 8536898

Group type: EXPERIMENTAL
Intervention: Nonionic, low osmolarity contrast media
Number of subjects: 1659

Group type: COMPARATOR
Intervention: Standard ionic contrast media
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Diagnostic ERCP
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Therapeutic procedures
Number of subjects: 1659

Group type: EXPERIMENTAL
Intervention: Sphincter of Oddi manometry
Number of subjects: 1659